|
|
All research proposals must be reviewed and approved by the RDA before submission.
|
|
NSF-BSF New Programs
We are happy to inform you that the NSF-BSF joint funding
programs have been expanded to include Mathematical Sciences, Astronomical
Sciences and Atmospheric and Geospace Sciences. It is now possible to submit to
the NSF joint applications by U.S. and Israeli scientists in these
disciplines, effective immediately.
Please be reminded that the BSF allows concurrent submission
to both the regular program and to the NSF-BSF programs, including the
same research program. However, if the submissions are similar, or
significantly overlap, only the NSF-BSF program will be funded.
In addition, the BSF now allows the submission of up to 2 NSF-BSF applications concurrently, as long as one of them is to a program with no deadline.
|
|
|
Recovery of Species on the Brink of Extinction | |
In partnership with the IUCN SSC and Fondation Segré, the goal of this funding is to halt further biodiversity decline by implementing conservation plans for species and groups of species.
Proposals that focus on the following themes are encouraged:
- Specific and defensible priority actions to avert decline of a species or group of species
- Projects that include the active involvement of early career conservationists
- Projects that support conservation leaders from the countries where the species or group of species occur
|
|
|
|
AI for Earth Innovation | |
The National Geographic Society and Microsoft’s AI for Earth program are partnering to support novel projects that create and deploy AI tools to improve the way we monitor, model, and ultimately manage Earth’s natural systems for a more sustainable future.
As an additional opportunity, Microsoft will help the successful proposals make the completed models available for use by other environmental researchers and innovators.
For more information about, please email National Geographic (“AI for Earth Innovation” in the subject line).
|
|
|
| | |
RDA Deadline (RFP) -
October 2, 2019
|
Drug Discovery Program | |
The Alzheimer's Drug Discovery Foundation (ADDF) has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer's disease, related dementias, and cognitive aging by supporting promising therapeutic approaches.
The Drug Discovery RFP supports:
-
Novel drug programs aiming to advance novel lead molecules to the clinical candidate selection stage.
-
Repurposed/repositioned programs
aiming to build preclinical evidence in relevant animal models for repurposed drugs and repositioned drugs.
Call Details
|
|
|
Program to Accelerate Clinical Trials - PACT | |
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer's disease and related dementias.
The PACT RFP supports:
-
Early-stage human clinical trials,
-
Experimental medicine
-
Regulatory studies for novel drugs (small molecules and biologics including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.
|
|
|
|
Neuroimaging and CSF Biomarker Development Program | |
Given the pathological heterogeneity of Alzheimer's disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology.
This RFP seeks to support the development of CSF (Cerebrospinal fluid) and neuroimaging biomarkers for multiple contexts of use, that include:
-
Clearly demonstrate target engagement for novel therapeutics
- Detect signs of disease earlier and monitor progression
- More accurately diagnose and distinguish between dementia subtypes
|
|
|
Prevention Beyond the Pipeline | |
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
Funding Priorities:
-
Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) - Collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script
-
Comparative Effectiveness Research
- Generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia.
-
Cognitive Decline and Cognitive Reserve
|
|
|
| | |
RDA Deadline (LOI) -
October 2, 2019
|
|
The Israel Academy of Sciences and Humanities
Since 2001, The Israel Academy of Sciences and Humanities and the Monumenta Germaniae Historica, Munich - the central institution that publishes critical editions of texts written in medieval Germany – have jointly published a series of
scientific editions of Hebrew essays written in the Middle Ages in Ashkenaz
.
The editions are written in Hebrew, each with an introduction and a translation in German or English, and a summary of the introduction in Hebrew. Several volumes have been published and two additional volumes are in preparation.
The Academy of Sciences is now requesting
proposals for the publication
of
these works
.
The responsibility for locating all the relevant manuscripts will be on the editor and will include a historical introduction.
Contacts:
Maya Rotem, 64 77742 (Faculty of Humanities and Social Sciences)
Submission Deadline: October 22, 2019
|
|
|
|
IMI2 Call 18 – Innovative Medicines Initiative- Pre-Proposal
The Innovative Medicines Initiative has launched Call 18 in the following topics:
Deadline: 2-stage call for proposals. Deadline for first stage: 26 September 2019 (17:00:00 Brussels time)
For more information please contact Lori Liss, Tel: 64 72435
|
|
|
|
| |
|
.jpg)
.jpg)
.png){kind=spacer}
.png)
.png)
smoove marketing platform